Overview

Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer

Status:
Active, not recruiting

Trial end date:
2022-08-01

Target enrollment:

Participant gender:

Summary

This study will evaluate the safety and efficacy of VE800 in combination with Nivolumab in patients with selected types of advanced or metastatic cancer

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Vedanta Biosciences, Inc.

Collaborators:

Bristol-Myers Squibb
Bristol-Myers Squibb (BMS)

Treatments:

Nivolumab
Vancomycin